EP3641728B9 - An oil-in-water nanoemulsion composition of clobetasol - Google Patents

An oil-in-water nanoemulsion composition of clobetasol Download PDF

Info

Publication number
EP3641728B9
EP3641728B9 EP18700437.9A EP18700437A EP3641728B9 EP 3641728 B9 EP3641728 B9 EP 3641728B9 EP 18700437 A EP18700437 A EP 18700437A EP 3641728 B9 EP3641728 B9 EP 3641728B9
Authority
EP
European Patent Office
Prior art keywords
oil
clobetasol
sodium
comprised
nanoemulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18700437.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3641728B1 (en
EP3641728A1 (en
Inventor
Javier SANAGUSTIN AQUILUE
María Del Carmen LENDÍNEZ GRIS
Maria Isabel DELGADO GAÑÁN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Salvat SA
Original Assignee
Laboratorios Salvat SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Salvat SA filed Critical Laboratorios Salvat SA
Priority to PL18700437T priority Critical patent/PL3641728T3/pl
Priority to SI201830297T priority patent/SI3641728T1/sl
Publication of EP3641728A1 publication Critical patent/EP3641728A1/en
Application granted granted Critical
Publication of EP3641728B1 publication Critical patent/EP3641728B1/en
Priority to HRP20210865TT priority patent/HRP20210865T1/hr
Publication of EP3641728B9 publication Critical patent/EP3641728B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to the field of pharmacy.
  • it relates to compositions containing clobetasol.
  • the present invention relates to oil-in-water nanoemulsion compositions of clobetasol, processes for their preparation, as well as their use as a medicament and particularly in the prophylaxis and/or treatment of inflammatory diseases or conditions.
  • Clobetasol propionate is the International Nonproprietary Name (INN) of [17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate having the CAS number 25122-46-7 .
  • the structure of clobetasol propionate corresponds to the formula (I):
  • Clobetasol propionate is a corticosteroid of the glucocorticoid class used for the treatment of various inflammatory diseases.
  • clobetasol propionate is used for the treatment of skin disorders including eczema, herpes labialis, psoriasis, and lichen sclerosus. It is also used to treat several auto-immune diseases including alopecia areata, vitiligo, lichen planus (auto immune skin nodules), and mycosis fungoides (T-cell skin lymphoma). It has very high potency and typically should not be used with occlusive dressings, or for extended continuous use. It can be in form of topical formulations such as shampoo, mousse, ointment and emollient cream presentations.
  • clobetasol propionate exhibit a strong anti-inflammatory action and therefore, useful in the form of an eye drops for the treatments of various ocular diseases, for instance, inflammatory diseases of external- and anterior-ocular sites such as blepharitis, conjunctivitis, keratitis, scleritis, episcleritis, ulceris, iridocyclitis and uveitis as well as inflammatory diseases developed after ocular operations.
  • the European patent number EP0844001 discloses an oil-in-water emulsion of clobetasol propionate comprising liquid paraffin oil and a phospholipid for being instilled in the eye.
  • the emulsions have well recognized limitations for ocular administration, as blurred vision or lack of patient compliance due to the vicosity of formulations.
  • these emulsions have limited bioavailability and permeability
  • the ocular bioavailability following topical administration of emulsions to the eye remains a challenge still not satisfactorily resolved.
  • oil-in-water emulsions of clobetasol comprising eucalyptus oil, tween and ethylalcohol have been also disclosed in the state of the art ( Mohammad Sajid Ali. "Accelerated stability testing of a clobetasol propionate loaded nanoemulsion as per ICH guideline”. Scientia Pharmaceutica, vol. 81, no.4, 1 January 2013 (2013-01-01), pp. 1089-1100 ).
  • the weight ratio between the oil component and clobetasol of these emulsions is 272:1 and the weight ratio between the surfactant and clobetasol is 385:1.
  • the osmolarity is outside the range 100-500mOsm/Kg and the average droplet size measured by DLS is above 6000 nm, which means that the droplet size of these emulsions does not correspond to nanoemulsions droplet average size range (about 1 - 500 nm).
  • these emulsions are physically unstable and differentiated into three phases. In addition, they are also irritant after application in such a degree that they are must be considered unsuitable for ocular or otic applications.
  • an additional constrain for the ocular compositions is their sterilization. It is disclosed in the state of the art several techniques to sterilizate ocular compositions that involve thermic or radiation procedures that may impact on clobetasol stability. In particular, the compositions disclosed in the European patent number EP0844001 requires a complex manufacturing process to get an uniform distribution of active ingredient that may compromise the stability of the drug substance, even more for a highly sensitive molecule like clobetasol.
  • the PCT patent application WO2017037663 discloses a topical oil-in-water nanoemulsion of clobetasol propionate for the treatment of psoriasis, wherein the composition comprises a high amount of alcohols, oil components and surfactants.
  • the compositions disclosed in this patent application still have problems of non-appropriate tolerability in ocular or mucous membranes due to high proportion of solvents or non-suitable components for those routes of administration.
  • the method for obtaining such compositions requires high energy methods that impair the stability behaviour of the drug.
  • the PCT patent application WO2017037663 is silent about the release of the active ingredient from the composition and the related activity is not demonstrated.
  • Inventors have found a stable oil-in-water nanoemulsion composition containing clobetasol and having a low content of oil components and surfactants as well as a specific weight ratio between the oil component or the surfactant in relation to the amount of the active ingredient and a specific weight ratio between the amount of oils in relation to the sum of oil components and surfactants which allows having a good feeling after application and also appropriate pharmacokinetic and pharmacodynamics properties for the prophylaxis and/or treatment of inflammatory diseases or conditions.
  • the nanoemulsion composition of the invention has good stability, even a good stability of the active ingredient or the final composition.
  • the nanoemulsion composition of the invention also permits a good release and absorption of the effective amount of clobetasol to the treatment area with less side effects associated to an unduly distribution of clobetasol.
  • the nanoemulsion of the invention has also a comfortable feeling and tolerability after administration.
  • a first aspect of the invention relates to an oil-in-water nanoemulsion composition having a continuous aqueous phase and dispersed oil droplets, wherein the nanoemulsion comprises: (a) a therapeutically effective amount of clobetasol or a pharmaceutically acceptable salt or ester thereof; (b) one or more oil components; and (c) one or more surfactants; together with one or more pharmaceutically acceptable excipients or carriers wherein: the osmolality of the nanoemulsion composition is comprised from 100 mOsm/Kg to 500 mOsm/Kg; the droplet average size measured by Dynamic light scattering is comprised from 1 nm to 500 nm; the weight ratio between the oil components and the sum of the oil components and one or more surfactants is comprised from 0.001 to 0.5; the weight ratio between the oil component and clobetasol or a pharmaceutically acceptable salt or ester thereof is comprised from 1:1 to 200:1; and the weight ratio between the surfactant and
  • a second aspect of the invention relates to a process for the preparation of the oil-in-water nanoemulsion composition as defined in the first aspect of the invention, which comprises: (a) preparing the oil phase by mixing clobetasol with the oil components and the surfactants; (b) preparing the aqueous phase; (c) emulsifying the oil phase obtained in step (a) in the aqueous phase obtained in step (b); (d) optionally, adjusting the pH; the osmolality; the pH and the osmolality after step (a), step (b) or step (c); and (e) optionally, adding one or more additional pharmaceutically acceptable excipients or carriers in step (a), step (b) or step (c).
  • a third aspect of the invention relates to an oil-in-water nanoemulsion composition as defined in the first aspect of the invention, for use as a medicament.
  • the fourth aspect of the invention relates to an oil-in-water nanoemulsion composition as defined in the first aspect of the invention, for use in the prophylaxis and/or treatment of an inflammatory diseases or conditions.
  • Fig. 1 shows the images obtained after performing the HET-Cam ocular irritation assay of the composition 11 of the present invention (A) and of the comparative composition 34 outside the scope of the present invention (B). The images were done at the initial time of the assay (1) and at the end of the assay (2) (5 minutes).
  • any ranges given include both the lower and the upper end-points of the range.
  • clobetasol used herein in the application refers to a compound of formula (II).
  • Clobetasol can be in form of a salt or in form of an ester. Particularly, the clobetasol can be in form of its propionate ester corresponding to the compound of formula (I) as defined above.
  • nanoemulsion refers to a colloidal dispersed system comprising at least two immiscible phases, one phase dispersed in the other phase as droplet having an average size measured by Dynamic light scattering from 1 nm to 500 nm.
  • average size and mean size have the same meaning and are used interchangeable. They refer to average diameter of the droplets.
  • the average size of these systems can be measured by standard processes known by persons skilled in the art.
  • average size and mean size is understood a D(n,50) droplet average size in number.
  • the D(n,50) droplet average size is the median diameter, where 50% of the droplets are composed of droplets larger than the stated value, and 50% of the droplets are composed of droplets smaller than the stated value.
  • the measurement of the average size of the droplets was performed by dynamic light scattering (DLS).
  • DLS makes use of two common characteristics of colloids, the Tyndall effect (scattering) and the Brownian motion which cause light to be scattered at different intensities. Analyses of the time depend on the intensity fluctuations using mathematical models, allows the determination of the average size (cf. Hassan, P. et al, "Making sense of Brownian motion: colloid characterization by dynamic light scattering", Langmuir, 2015, vol. 31, pp.3-12 ).
  • the droplets are constantly moving due to Brownian motion and the relationship between the size of a droplets and its speed due to Brownian motion is defined in the Stokes-Einstein equation. As the droplets move around, the scattered light will cause intensity fluctuations.
  • the signal intensity is compared at different times with itself in order to obtain the correlation function.
  • This information can then be used to calculate the size distribution by intensity and it can be converted to a volume or a number size distribution.
  • the diameter of the droplets i.e. the mean size of the droplets
  • the measurement of the average size (D(n,50)) of the droplets was directly measured (without dilution) by dynamic light scattering (DLS) with Zetasizer Nano ZS (Malvern Instruments) performing the calculations explained above in the present application.
  • the nanoemulsion composition of the invention is an oil-in-water nanoemulsion.
  • oil-in-water and “O/W” have the same meaning and are used interchangeable. They refer to a nanoemulsion wherein oil is dispersed as droplets throughout the aqueous phase.
  • percentage (%) by weight refers to the weight of each ingredient of the composition in relation to the total weight of the composition.
  • percentage (%) by volume refers to the volume each ingredient of the composition in relation to the total volume of the composition.
  • % (w/v) and “mass concentration” have the same meaning and are used interchangeable. They refer to the mass of a ingredient divided by the volume of the composition.
  • weight ratio refers to the relation in weight of a given compound to another given compound, for instance, between the oil component and clobetasol.
  • volume ratio refers to the relation in volume of a given compound to another given compound, for instance, between the acetonitrile and water in the comparative buffered solution samples.
  • osmolality refers to the moles of solute that contribute to a solution's osmotic pressure (or osmoles) per kilogram of solvent. The osmolality is determined by the measurement of the freezing point depression of the sample using an osmometer.
  • pH is defined as the value given by a suitable, properly standardized, potentiometric sensor and measuring system.
  • the measuring system has traditionally been referred to as the "pH meter”.
  • pH of the nanoemulsions are measured by compendial traditional methods.
  • the first aspect of the invention relates to an oil-in-water nanoemulsion comprising a therapeutically effective amount of clobetasol or a pharmaceutically acceptable salt or ester thereof.
  • therapeutically effective amount refers to the amount of clobetasol or a pharmaceutically acceptable salt or ester thereof that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disease or condition which is addressed.
  • the particular dose of clobetasol administered according to this invention will of course be determined by the particular circumstances surrounding the case, including the active clobetasol administered, the route of administration, the particular condition being treated, and similar considerations.
  • the clobetasol is in form of a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salt used herein encompasses a salt formed from pharmaceutically acceptable non-toxic acids including inorganic or organic acids. There is no limitation regarding the salts, except that if used for therapeutic purposes, they must be pharmaceutically acceptable. Salts of clobetasol may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • Such acids include among others acetic, benzene sulfonic, benzoic, camphor sulfonic, citric, ethansulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, lactic, maleic, malic, mandelic, methanesulfonic, phosphoric, succinic, sulphuric, tartaric, and p-toluensulfonic acid.
  • the clobetasol is in form of a pharmaceutically acceptable ester.
  • pharmaceutically acceptable ester used herein encompasses an ester formed from pharmaceutically acceptable non-toxic acids including inorganic or organic acids. There is no limitation regarding the ester, except that if used for therapeutic purposes, they must be pharmaceutically acceptable. Esters of clobetasol may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • Such acids include among others acetic, butyric, propionic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethansulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, lactic, maleic, malic, mandelic, methanesulphonic, phosphoric, succinic, sulphuric, tartaric and p-toluensulphonic acid.
  • the clobetasol is in form of ester selected from the group consisting of clobetasol butyrate and clobetasol propionate; preferably clobetasol propionate of formula (I).
  • the composition of the invention is one wherein the therapeutically effective amount of clobetasol is comprised from 0.001 % to 0.1 % by weight, preferably comprised from 0.01 % to 0.05 % by weight; more preferably 0.05 % by weight.
  • the composition is one comprising from 0.001 % to 0.1 % by weight of clobetasol propionate; preferably comprised from 0.01 % to 0.05 % by weight of clobetasol propionate.
  • oil is used herein in a general sense to identify a wide class of substances typically unctuous, viscous and liquid at room temperature. Oil as here in defined can be from animal, mineral, vegetable or synthetic origin.
  • oil component refers to oil, or a combination of multiple oils in a colloidal dispersion.
  • room temperature refers to a temperature of the environment, without heating or cooling, and is generally from 20 °C to 25 °C.
  • the oil component of the nanoemulsion of the present invention is a (C 4 -C 20 ) alkyl ester of monoglyceride, diglyceride, or triglyceride and mixture thereof.
  • the (C 4 -C 20 ) alkyl ester of monoglyceride, diglyceride or triglyceride is medium chain triglycerides.
  • the term “Medium chain triglycerides” and “MCT” have the same meaning and are used interchangeable and refers to triesters of glycerin and (C 6 -C 12 ) fatty acids.
  • MCTs examples include caproic acid (C 6 ), caprylic acid (C 8 ), capric acid (C 10 ) and lauric acid (C 12 ).
  • the three fatty acid residues of the MCT can be the same or different, preferably there are two different fatty acid residues.
  • the oil is a medium chain triglyceride selected from caproic acid, caprylic acid, capric acid, lauric acid and mixture thereof; preferably the oil is a caprylic/capric acid triglyceride.
  • the nanoemulsion compositions of the invention which comprise MCT as oil component are especially advantageous because the solubility of clobetasol in MCT is very high, and then the use of MCT allows the reduction of oil content in the nanoemulsion of the invention.
  • the oil component of the nanoemulsion of the present invention is other than monoglyceride, diglyceride or triglyceride esters, selected from the group consisting of ethyl oleate, decyl oleate, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, isostearyl isostearate, glyceryl monosterate, myristyl lactate, ethylhexyl hydroxystearate, ethylhexyl pelargonate, triethylhexanoin, isohexadecane, light mineral oil, mineral oil, vegetable oil, triisononanoin, (C 12 -C 15 ) alkyl benzoate, and mixtures thereof; preferably, selected from the group consisting of ethyl oleate, isopropyl myristate, isopropyl palmitate, isopropyl is
  • alkyl refers to a saturated, branched or linear alkyl chain which contains the number of carbon atoms specified in the description or claims.
  • vegetable oil refers to a triglyceride extracted from a plant.
  • examples of vegetable oils are argan oil, corn oil, palm oil, coconut oil, cottonseed oil, olive oil, peanut oil, rapeseed oil, sunflower oil, sesame oil, soybean oil, safflower oil, castor oil, olive oil, and mixture thereof.
  • the oil component is a mixture of a (C 6 -C 12 ) alkyl ester of monoglyceride, diglyceride, or triglyceride and an oil other than monoglyceride, diglyceride or triglyceride esters as defined above.
  • the oil is a mixture of MCTs and castor oil.
  • the weight ratio between the oil component and clobetasol or a pharmaceutically acceptable salt or ester thereof is comprised from 1:1 to 200:1.
  • the weight ratio between the oil component and clobetasol or a pharmaceutically acceptable salt or ester thereof is comprised from 1:1 to 100:1; preferably comprised from 1:1 to 90:1.
  • surfactant refers to a compound that lowers the surface tension or interfacial tension between two liquids or between a liquid and a solid.
  • Surfactants have a hydrophobic part and a hydrophilic part. Depending on the nature of the hydrophilic part the surfactants are classified as non-ionic (surfactant with a non-charged but polar hydrophilic part), anionic (when the hydrophilic part contains a negatively charged group), cationic (when the hydrophilic part contains a positively charged group) or amphoteric (when the when the hydrophilic part contains has both cationic and anionic groups).
  • the one or more surfactants of the nanoemulsion of the present invention are non-ionic surfactants.
  • non-ionic surfactants include, but are not limited to, (C 30 -C 40 )alkyl poly(ethylene oxide), block copolymers of poly(ethylene oxide) and poly(propylene oxide) (commercially called Poloxamers or Poloxamines), (C 8 -C 14 )alkyl polyglucosides including octyl glucoside and decyl maltoside, fatty alcohols including cetyl alcohol and oleyl alcohol, cocamide MEA, cocamide DEA, sorbitan esters and derivatives thereof or sorbitan esters ethoxylate and derivatives thereof.
  • the one or more surfactant of the nanoemulsion of the present invention is a non-ionic surfactant selected from the group consisting of polyoxyl castor oil with 30 to 40 oxyethylene units, in particular polyoxyl 35 castor oil (also known as polyethylene glycol 35 castor oil; marketed as Kolliphor® EL, Cremophor® EL), polyoxyl hydrogenated castor oil with 40 to 60 oxyethylene units, in particular polyoxyl 40 hydrogenated castor oil (also known as polyethylene glycol 40 hydrogenated castor oil; marketed as Cremophor® RH40), polyoxyethylene 20 sorbitan monooleate (also known as polysorbate 80 and marketed as Tween® 80), polyoxyethylene 20 sorbitan monostearate (also known as polysorbate 60 and marketed as Tween® 60), polyoxyethylene 20 sorbitan trioleate (also known as polysorbate 85 marketed as Tween® 85), polyoxyethylene 20 sorbitan tristearate (also known as polysorbate 65
  • the one or more surfactant of the nanoemulsion of the present invention is a non-ionic surfactant selected from the group consisting of polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyethylene 20 sorbitan monooleate, polyoxyethylene 20 sorbitan monostearate polyoxyethylene 20 sorbitan trioleate, polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene 20 sorbitan tristearate, polyoxyethylene 20 sorbitan monopalmitate, polyethylene glycol hexadecyl ether, glyceryl stearate, D- ⁇ -Tocopherol polyethylene glycol 1000 succinate (TPGS), poloxamer 188, poloxamer 407, polyoxy 40 stearate, sorbitan monolaurate, octoxynol 40 and mixtures thereof.
  • the one or more surfactant of the nanoemulsion of the present invention is a non-ionic surfactant selected from the group consisting of polyoxy
  • the one or more surfactant of the nanoemulsion of the present invention is a non-ionic surfactant selected from the group consisting of sorbitan esters ethoxylates derivatives, sorbitan esters derivatives, poly(ethylene oxide)-poly(propylene oxide) copolymers, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 40 stearate, octoxynol 40, D- ⁇ -Tocopherol polyethylene glycol 1000 succinate (TPGS), and mixtures thereof.
  • sorbitan esters ethoxylates derivatives sorbitan esters derivatives
  • poly(ethylene oxide)-poly(propylene oxide) copolymers polyoxyl 35 castor oil
  • polyoxyl 40 hydrogenated castor oil polyoxyl 40 stearate
  • octoxynol 40 D- ⁇ -Tocopherol polyethylene glycol 1000 succinate (TPGS)
  • TPGS D- ⁇ -Tocopherol polyethylene glyco
  • the weight ratio between the surfactant and clobetasol or a pharmaceutically acceptable salt or ester thereof is comprised from 2:1 to 200:1.
  • the weight ratio between the surfactant and clobetasol or a pharmaceutically acceptable salt or ester thereof is comprised from 2:1 to 190:1; preferably comprised from 2:1 to 180:1.
  • the nanoemulsion of the invention has a weight ratio between the oil components and the sum of the oil components and the one or more surfactants comprised from 0.001 to 0.5.
  • the weight ratio between the oil components and the sum of the oil components and the surfactants is comprised from 0.001 to 0.4; preferably comprised from 0.005 to 0.4; more preferably comprised from 0.005 to 0.3.
  • the nanoemulsion of the invention has an osmolality comprised from 100 mOsm/Kg to 500 mOsm/kg; preferably comprised from 150 mOsm/Kg to 400 mOsm/kg.
  • the osmolality is comprised from 120 mOsm/Kg to 380 mOsm/Kg. It is advantageous because these compositions are isotonic and hence suitable for ocular administration.
  • the nanoemulsion of the invention has a droplet average size comprised from 1 nm to 500 nm; preferably comprised from 1 nm to 250 nm.
  • the droplet average size measured by Dynamic light scattering is comprised from 1 nm to 250 nm. It is advantageous because the nanoemulsion composition is transparent and avoids the uncomfortable feeling of blurry vision.
  • the nanoemulsion of the invention has a pH comprised from 4.0 to 8.0; preferably comprised from 4.5 to 7.4.
  • the pH of the composition comprises from 4.5 to 7.4 as the pH of tear fluid.
  • the nanoemulsion of the invention has an amount of ethanol comprised from 0 % to 3 % by weight; preferably the amount of ethanol is comprised from 0 % to 2 % by weight. It is advantageous because the lower amount of ethanol allows reducing the uncomfortable feeling of use in ophthalmic, nasal or buccal administration routes.
  • the nanoemulsion of the invention also comprises one or more pharmaceutically acceptable excipients or carriers.
  • acceptable excipients or carriers refers to acceptable material, composition or vehicle, which include without limitation pH adjusting agents, preservatives, antioxidants, chelating agents, stabilizers, viscosizing agents, adhesive polymers, penetration enhancers and tonicity agents.
  • pH adjusting agents include without limitation pH adjusting agents, preservatives, antioxidants, chelating agents, stabilizers, viscosizing agents, adhesive polymers, penetration enhancers and tonicity agents.
  • Each component must be acceptable in the sense of being compatible with the other ingredients of the composition. It must also be suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications commensurate with a reasonable benefit/risk ratio.
  • the nanoemulsion of the invention further comprises one or more pH adjusting agents.
  • pH adjusting agent refers to acids or bases or their mixtures that can be used to adjust the pH of the finished product to the desired level, without affecting the stability of the emulsion.
  • the nanoemulsion of the invention further comprises a pH adjusting agent selected from the group consisting of lactic acid and salts thereof (such as sodium lactate, potassium lactate and calcium lactate), citric acid and salts thereof (such as sodium citrate, potassium citrate, calcium citrate, lithium citrate, trisodium citrate and disodium hydrogen citrate), tartaric acid and salts thereof (such as sodium tartrate potassium tartrate, calcium tartrate and lithium tartrate), acetic acid and salts thereof (such as sodium acetate, potassium acetate and calcium acetate), hydrochloric acid, boric acid and salts thereof (sodium borate), sulphuric acid and salts thereof (such as sodium sulphate and potassium sulphate), nitric acid, hydrochloric acid, phosphoric acid and salts thereof (such as sodium dihydrogen phosphate, sodium monohydrogen phosphate, potassium dihidrogen phosphate lithium phosphate, potassium phosphate and calcium phosphate), carbonic acid and salts thereof (
  • the pH adjusting agent is selected from the group consisting of tris(hydroxymethyl)aminomethane, tris(hydroxymethyl)aminomethane hydrochloride, potassium dihydrogen phosphate, disodium hydrogen phosphate and mixtures thereof.
  • the nanoemulsion of the invention further comprises a pH adjusting agent selected from the group consisting of acetic acid, boric acid, sorbic acid, citric acid, phosphoric acid, sodium phosphate, dibasic sodium phosphate, monobasic sodium phosphate, potassium dihydrogen phosphate and salts thereof, hydrochloric acid, sodium hydroxide, sodium thiosulfate, sodium sulfite, sodium sulphate, tris(hydroxymethyl)aminomethane, tris(hydroxymethyl)aminomethane hydrochloride, sodium hydrogen carbonate, sodium borate, sodium acetate, sodium bisulphate, sodium benzoate, sodium citrate and mixtures thereof.
  • the pH adjusting agent is tris(hydroxymethyl)aminomethane and salts thereof.
  • the amount of the pH adjusting agent in the nanoemulsion of the present invention is comprised from 0.01 % to 3 % by weight.
  • the nanoemulsion of the invention further comprises one or more stabilizers.
  • stabilizer refers to a compound that enhanced the stability of the nanoemulsion and/or of the active ingredient.
  • the stabilizer is a water soluble polymer for instance polyvinylpyrrolidone, polyvinyl alcohol, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, salt thereof, and mixture thereof; preferably polyvinylpyrrolidone.
  • the stabilizer is tris(hydroxymethyl)aminomethane and or tris(hydroxymethyl)aminomethane hydrochloride.
  • the use of the tris(hydroxymethyl)aminomethane and salts thereof is especially advantageous because allows a reduction in the total amount of degradation products, which means that the stability of the active ingredient in the nanoemulsion of the invention is higher than in the emulsions disclosed in the state of the art.
  • the amount of the stabilizer in the nanoemulsion of the present invention is comprised from 0.01 % to 15 % by weight.
  • the nanoemulsion of the invention further comprises one or more bioadhesive polymers.
  • bioadhesive polymers refers to a substance which can increase residence time of the compositions of the invention.
  • bioadhesive polymers include polyvinylpirrolidones, such as Povidone K 17, Povidone K25, Povidone K 30 and Povidone K 90F; polyvinyl alcohol; xanthan gum; guar gum; welan gum; gellan gum; tragacanth gum; ceratonia gum; agar; methylcellulose; ethylcellulose; hydroxyethyl cellulose; hydroxyethylmethyl cellulose; hydroxypropyl cellulose; hydroxypropylmethyl cellulose; hydroxypropylmethyl cellulose phthalate; hydroxypropylmethyl cellulose acetate succinate; sodium carboxymethylcellulose; calcium carboxymethylcellulose; polyethylene glycol; glycerine; carrageenan; algin
  • compositions of the invention comprise polyvinylpyrrolidone as bioadhesive polymer.
  • bioadhesive polymer is present in an amount of from 0.01 % to 15 % by weight with respect to the total weight of the compositions.
  • the nanoemulsion of the invention further comprises one or more preservatives.
  • preservative refers to a compound that preserve from microbial and/or fungal contaminations.
  • examples of preservatives appropriate for the present invention include but is not limited to benzalkonium chloride, cetalkonium chloride, bezethonium chloride, chlorhexidine, benzyl alcohol, chlorobutanol, 2-phenylethanol, propylparaben, methylparaben, phenylmercuric acetate, phenylmercuric borate, sodim dehydroacetate, sorbic acid phenylmercuric nitrate, cetyl pyridinium chloride, cetrimonium bromide, benzyl bromide, sodium perborate, thimerosal and mixture thereof.
  • the amount of the preservative in the nanoemulsion of the present invention is comprised from 0 % to 1 % by weight.
  • the nanoemulsion of the invention further comprises one or more tonicity agent.
  • the term "tonicity agent" refers to a compound that can be used for adjusting the osmolality of the nanoemulsion.
  • the tonicity agent is selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, sodium phosphate, potassium phosphate, sodium hydrogen carbonate, calcium carbonate, sodium lactate, sorbitol, mannitol, xylitol, dextrose, polyethylene glycol, propylene glycol, dextran, and mixture thereof; preferably glycerin.
  • the amount of the tonicity agent in the nanoemulsion of the present invention is comprised from 0 % to 15 % by weight.
  • the nanoemulsion of the invention further comprises one or more chelating agent.
  • chelating agent and “chelant” have the same meaning and are used interchangeable. They refer to a compound that is capable of complexing ions.
  • chelating agents are citric acid, in particular citric acid monohydrate, EDTA (ethylenediaminetetraacetic acid) and its salts, such as dipotassium EDTA, disodium EDTA, calcium disodium EDTA, sodium EDTA and trisodium EDTA, fumaric adid, malic acid and maltol.ln an embodiment, the chelating agent is selected from the group consisting of sodium edetate, citric acid, and salt and mixture thereof.
  • the amount of the chelating agent in the nanoemulsion of the present invention is comprised from 0 % to 2 % by weight.
  • penetration enhancer refers to a substance which enhances drug penetration.
  • penetration enhancers are surfactants such as sorbitan monolaurate, sorbitan monopalmitate, sorbitan trioleate, polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 5 sorbitan monooleate, polyoxyethylene 20 sorbitan trioleate, polyoxyethylene 9 lauryl ether, polyoxyethylene 23 lauryl ether, polyoxyethylene 20 cetyl ether, polyoxyethylene 20 oleyl ether, polyethylene glycol octadecyl ether, polyoxyethylene 40 stearate, polyoxyethylene 50 stearate, palmitoyl carnitine, sodium caprate, sodium dodecyl sulfate, bile acids such as deoxycholic acid, taurocholic acid, taurodeoxycholic acid, urodeoxycholic acid, and taurours
  • bile acids such as deoxy
  • the nanoemulsion of the present invention comprises: from 0.001 % to 0.1 % by weight of clobetasol or a pharmaceutically acceptable salt or ester thereof; preferably clobetasol propionate; from 0.001 % to 20 % by weight of one or more oil components; from 0.002 % to 20 % by weight of one or more surfactants; water in a sufficient amount for 100 %; and optionally, a pH adjusting agent in a sufficient amount for having a pH comprised from 4.0 to 8.0; and optionally, an tonicity agent in a sufficient amount for having an osmolality comprised from 100 mOsm/kg to 500 mOsm/Kg.
  • the nanoemulsion of the present invention comprises: from 0.01 % to 0.05 % by weight of clobetasol pharmaceutically acceptable salt or ester thereof; clobetasol propionate; from 0.01 % to 10 % by weight of one or more oil components; from 0.02 % to 10 % by weight of one or more surfactants; water in a sufficient amount for 100 %; and optionally, a pH adjusting agent in a sufficient amount for having a pH comprised from 4.0 to 8.0; and optionally, an tonicity agent in a sufficient amount for having an osmolality comprised from 100 mOsm/Kg to 500 mOsm/Kg.
  • the nanoemulsion of the present invention comprises: from 0.001 % to 0.1 % by weight of clobetasol or a pharmaceutically acceptable salt or ester thereof; preferably clobetasol propionate; from 0.001 % to 20 % by weight of medium chain fatty acid triglyceride; from 0.002 % to 20 % by weight of polyoxyethylene 20 sorbitan monooleate; water in a sufficient amount for 100 mL; optionally, tris(hydroxymethyl)aminomethane in a sufficient quantity for having a pH comprised from 4.0 to 8.0; and optionally, glycerine in a sufficient quantity for an osmolality comprised from 100 mOsm/Kg to 500 mOsm/Kg.
  • the nanoemulsion of the present invention comprises: from 0.01 % to 0.05 % by weight of clobetasol or a pharmaceutically acceptable salt or ester thereof; preferably clobetasol propionate; from 0.01 % to 10 % by weight of medium chain fatty acid triglyceride; from 0.02 % to 10 % by weight of polyoxyethylene 20 sorbitan monooleate; water in a sufficient amount for 100 mL; optionally, tris(hydroxymethyl)aminomethane in a sufficient quantity for having a pH comprised from 4.0 to 8.0; and optionally, glycerine in a sufficient quantity for an osmolality comprised from 100 mOsm/Kg to 500 mOsm/Kg.
  • the nanoemulsion composition of the invention is an ophthalmic composition, otic composition, nasal composition or buccal composition.
  • the nanoemulsion composition of the invention is in form of eye drops, ear drops, nose drops or oral spray.
  • the nanoemulsion composition is an ophthalmic composition which is in form of eye drops. It is advantageous because the nanoemulsion of the present invention is transparent avoiding uncomfortable feeling after use such as blurry vision and burning.
  • the nanoemulsion is an ophthalmic composition it should be sterile.
  • sterile refers to a nanoemulsion composition that has been aseptically processed and that is devoid of viable bacteria, fungi or other microorganisms.
  • the nanoemulsion composition is a sterile ophthalmic composition.
  • the nanoemulsion composition is a multi-dose ophthalmic composition and the composition further comprises a preservative as defined above.
  • the nanoemulsion composition is a uni-dose ophthalmic composition. It is advantageous because these nanoemulsions do not require the inclusion in the composition of preservatives.
  • the second aspect of the invention relates to a process for the preparation of the nanoemulsion as defined above.
  • the nanoemulsion compositions of the present invention can be prepared according to methods well known in the state of the art for the preparation of nanoemulsion, particularly to oil-in-water nanoemulsion.
  • the appropriate excipients and/or carriers, and their amounts, can readily be determined by those skilled in the art according to the type of formulation being prepared.
  • the process for the preparation of the nanoemulsions of the present invention is performed by phase inversion composition (PIC).
  • the process for the preparation of the oil-in-water nanoemulsion composition as defined above comprises: (a) preparing the oil phase by mixing clobetasol with the oil components and the surfactants; (b) preparing the aqueous phase; (c) emulsifying the oil phase obtained in step (a) in the aqueous phase obtained in step (b); (d) optionally, adjusting the pH; the osmolality; the pH and the osmolality after step (a), step (b) or step (c); and (e) optionally, adding one or more additional pharmaceutically acceptable excipients or carriers in step (a), step (b) or step (c).
  • step (a) is performed by mixing in a suitable container until a homogenous mixture is obtained.
  • step (b) is performed by dissolving or dispersing the components of the aqueous phase. In an embodiment, step (b) is performed for the appropriate period of time for having an homogenous blend.
  • step (c) is performed by emulsifying the oil phase with the aqueous phase keeping a continuous mixing procedure at temperatures between 10 °C to 60 °C.
  • step (c) is performed when the temperature of the oil phase obtained in step (a) is close to the temperature of the aqueous phase obtained in step (b).
  • the expression "the temperature of the oil phase is close to the temperature of the aqueous phase” means that the temperature value is "approximate" due to the measurement error. It should be understood that "close” corresponds to a given temperature value ⁇ 10 °C. The variability of the values is due to the inherent sensibility of the method.
  • the nanoemulsion of the invention can be performed by a simple process under mild conditions and without the need of a homogenizing step at high pressure. Methods related to high energy procedures (for instance high pressure and ultrasounds) may negatively impact on shelf life of active ingredient and the stability of the final dosage form. Therefore, the process for preparing the nanoemulsion of the present invention is advantageous for the stability of the active ingredient.
  • the process as defined above further comprises a sterilization step.
  • the sterilization step is performed after step (a); step (b); step (c); step (d) or step (e).
  • the sterilization process is performed after step (e).
  • the sterilization step can be performed according to methods well known in the state of the art.
  • the sterilization step is performed by a method selected from the group consisting of filtration, autoclaving, heating, irradiation, and combination thereof; preferably the sterilization step is performed by filtration.
  • the process of the invention further comprises a sterilization filtration.
  • the nanoemulsion may be sterilised by filtration, which is advantageous because of the use of mild conditions and without the need of high temperatures or radiation procedures that may negatively impact on the stability of the active ingredient. Therefore, the process for preparing the nanoemulsion of the present invention which involves the sterilization filtration is advantageous for the stability of the active ingredient and the nanoemulsion.
  • the nanoemulsion composition of the present invention may be defined by its preparation process as defined above and therefore, the nanoemulsion composition of the invention obtainable by the process of the invention is considered part of the invention.
  • the expressions “obtainable”, “obtained” and equivalent expressions are used interchangeably, and in any case, the expression “obtainable” encompasses the expression “obtained”.
  • the third aspect of the invention relates to a nanoemulsion composition as defined above for use as a medicament.
  • the fourth aspect of the invention relates to a nanoemulsion composition as defined above for use in the prophylaxis and/or treatment of an inflammatory disease or condition.
  • This aspect could be also formulated as the use of a nanoemulsion composition as defined above for the preparation of a medicament for the prophylaxis and/or treatment of an inflammatory disease or condition.
  • It also relates to a method for the prophylaxis and/or treatment of a mammal suffering, or susceptible to suffer, from an inflammatory disease or condition, wherein the method comprises administering to said mammal the nanoemulsion composition as defined above which comprises a therapeutically effective amount of clobetasol or a pharmaceutically acceptable salt or ester thereof together with one or more pharmaceutically acceptable excipients or carriers.
  • the inflammatory disease or condition is selected from the group consisting of ophthalmic inflammatory disease or condition, otological inflammatory disease or condition, and oropharyngeal inflammatory disease or condition.
  • the inflammatory disease or condition is an ophthalmic inflammatory disease or condition.
  • the inflammatory disease or condition is an otological inflammatory disease or condition.
  • the otological inflammatory disease or condition is selected from the group consisting of external otitis for instance diffuse, localized or eczematous otitis; otitis media for instance acute or chronic; atopic dermatitis with ear canal involvement.
  • the inflammatory disease or condition is an oropharyngeal inflammatory disease or condition.
  • the oropharyngeal inflammatory disease or condition is selected from the group consisting of pharyngitis; acute epiglotitis; allergic laryngitis; noninfectious acute laryngitis; lichen planus; aphthous stomatitis and pemphigoid.
  • compositions of the invention are A. Compositions of the invention
  • Examples 1-22 illustrate nanoemulsions of the present invention which contain clobetasol propionate of formula (I).
  • Tables 1A-1C illustrates the quantitative composition of the nanoemulsion of Examples 1-22 following within the scope of the present invention, wherein the amount of the components is expressed in percentage (%) by weight of each ingredient in relation to the total weight of the composition.
  • the osmolality of the nanoemulsions of Example 1-22 is comprised from 100 mOsm/Kg to 500 mOsm/Kg
  • the droplet average size measured by Dynamic light scattering is comprised from 1 nm to 500 nm
  • the pH is comprised from 4.0 to 8.0.
  • Examples 23-33 illustrate compositions falling outside the scope of the present invention which contain clobetasol propionate of formula (I).
  • Tables 1D-1E illustrates the quantitative composition of the comparative compositions of Examples 23-33, wherein the amount of the components is expressed in percentage (%) by weight of each ingredient in relation to the total weight of the composition.
  • the comparative compositions 24, 25, 26 and 29 fall outside the scope of the present invention because the weight ratio between the oil components and the sum of the oil components and surfactant is 0.7 being above the proposed limit of 0.5. Furthermore the percentages of oils and surfactants are higher than those corresponding to the nanoemulsions of the present invention.
  • the comparative compositions 30 and 31 are nanoemulsions with weight ratios between the surfactant and the clobetasol or a pharmaceutical acceptable salt or ester thereof higher than 200:1.
  • the comparative compositions 23 and 27 fall outside the scope of the present invention because are not nanoemulsions.
  • compositions 23 and 27 are micellar solutions without the positive activity of oily components, and the composition 23 as well contains a high percentage of alcohol as described in the prior art of clobetasol formulations.
  • the composition 28 is a suspension, thus clobetasol propionate is not properly dissolved.
  • the compositions 32 and 33 are the placebos for the pharmacological studies.
  • Comparative buffered solutions illustrate compositions falling outside the scope of the present invention which contain clobetasol propionate of formula (I). These comparative buffered solutions are used in the stability test (cf. section 1.3.)
  • Table 2 illustrates the quantitative composition of the comparative buffered solutions at pH 6.0, pH 6.8 and pH 7.4, wherein the amount of the components is expressed in grams in relation to the final volume of the solution.
  • Table 2 Comparative buffered solutions pH Components units pH 6.0 pH 6.8 pH 7.4 Clobetasol propionate g 0.05 0.05 0.05 Sodium dihydrogen phosphate monohydrate g 1.30 0.98 0.53 Disodium hydrogen phosphate dihydrate g 0.11 0.51 1.10 Acetonitrile/water (volume ratio 1:1) ml q.s*100 q.s*100 q.s*100 "q.s.” means quantity sufficient
  • compositions of the invention are A. Compositions of the invention
  • compositions of Examples 1-22 of the present invention were prepared following the process as defined below:
  • Example 23 of the present invention was prepared following the process as defined below:
  • Example 27 of the present invention was prepared following the process herein described:
  • Example 28 of the present invention was prepared following the process herein described:
  • the comparative buffered compositions were prepared following the process herein described: The sodium dihydrogen phosphate monohydrate and disodium hydrogen phosphate dihydrate were dissolved in the acetonitrile/water (volume ratio 1:1) and immediately after the clobetasol propionate was dissolved in the resulting media.
  • Test samples The nanoemulsion composition of the invention of Example 11 was adjusted to a pH of 6.0, 6.8 and 7.4.
  • the chromatographic system employed consisted of an Agilent 1290 high performance liquid chromatography with ultraviolet detection at 240 nm.
  • a Kromasil C 18 (150 x 4.6 mm, 5 ⁇ m) column was used for separation of the impurities.
  • Samples were prepared by diluting approximately 1 g of the each composition with water/acetonitrile (1:1) volume: volume up to a final volume of 5 ml.
  • the samples were maintained at 70 °C for 24 hours at pH of 6.0, 6.8 and 7.4 respectively. After that time the samples were analysed.
  • Table 3 illustrates the percentage of the total amount of degradation products and any individual degradation product detected after maintaining the samples under the conditions mentioned in section B. In particular, the amount of any individual degradation product as well as the total amount of degradation products expressed in weight percent (%) is shown in the Table below.
  • Table 3 Degradation products (%) pH Test sample: Nanoemulsion of Example 11 adjusted at different pHs Comparative buffered solutions of section 1.1.C Any individual degradation product 6.0 0.29 1.0 6.8 0.26 3.2 7.4 0.34 15.8 Total degradation products 6.0 0.49 3.4 6.8 0.47 6.8 7.4 1.0 53.5
  • the clobetasol propionate present in the nanoemulsion of the present invention is much more stable at all tested pH than the clobetasol propionate carried in the comparative phosphate buffered solution.
  • the nanoemulsion compositions of the present invention improves the stability of clobetasol propionate if compared to solutions, furthermore the compositions of the invention also comply with the strict regulatory affairs requirements of the specification of the ICH Harmonised Tripartite Guideline Impurities in New Drug Products Q3B(R2).
  • the aim of the performance test for topical compositions is the measurement of the drug release from the dosage form.
  • the vertical diffusion cell (VDC or Franz cell) system is a simple, reliable, and reproducible mean of measuring drug release from coloidal dosage forms.
  • Drug release can be described by mathematical models based on diffusion equations like the model published by Higuchi, which is often used. This model describes the release of a drug as a function of the square root of time (slope ⁇ g/h 1/2 ) when sink conditions are maintained. The slope can be considered as the release rate of active ingredient from the tested composition.
  • Test samples The nanoemulsion compositions of the invention of Examples 7, 11 and 22.
  • Comparative samples The comparative compositions of Examples 26, 28 and 29.
  • Diffusive communication between the delivery system and the reservoir takes place through an inert, highly permeable support membrane (polysulfane Tuffryn membrane 0.45 ⁇ m).
  • the membrane keeps the product and the receptor medium separate and distinct.
  • the membrane was chosen to offer the least possible diffusional resistance and not to be rate controlling.
  • the release rate experiment was carried out at 32 °C ⁇ 1°C,.
  • the receptor medium was a 5% TPGS aqueous solution.
  • the test and comparative samples were placed over the membrane disposed in a 15-mm diameter orifice Franz cell. Sampling was performed during 4 h, and the volume withdrawn was replaced with fresh receptor medium.
  • the amount of clobetasol propionate in the acceptor was determined for every release cell at every sampling time following the analytical method for organic impurities described in the Clobetasol Propionate USP monograph available in the website of the pharmacopeia http://www.pharmacopeia.cn/v29240/usp29nf24s0_m18334.htmi#usp29nf24s0_m18334 on June 2017 ).
  • the average cumulative amount released ( ⁇ g) was calculated for the different formulations tested, and a linear function was established using the square root of time as independent variable. The slope was the main factor to evaluate the drug release rate from different compositions.
  • Table 4 illustrate the slope value expressed in ⁇ g/h 1/2 and the coefficient R 2 value.
  • Table 4 Example Slope ( ⁇ g/h 1/2 ) coefficient R 2
  • Example 7 38.3 0.9973
  • Example 11 42.1 0.9945 Comparative Example 28 0.7 0.9924 Comparative Example 29 6.5 0.9977
  • Example 22 29.1 0.9916 Comparative Example 26 4.8 0.9973
  • compositions of the present invention show a fast delivery of the active ingredient, meanwhile the comparative compositions has an incomplete and low delivery of clobetasol from the composition.
  • the high slope values confirm the fast delivery of clobetasol in the compositions of the invention (cf. Examples 7,11 and 22) meanwhile the comparatibe compositions (Examples 26, 28 and 29) show a low slope value which is correlated with a low and incomplete delivery.
  • the active ingredient carried in the nanoemulsions of the invention is released to the receptor media in a higher amount and rate compared to the comparative samples.
  • the efficacy of comparative compositions are compromised since the clobetasol have a limited access to the targeted biological tissues, meanwhile the nanoemulsions allow the right release of active ingredient.
  • This behaviour is specially suitable for ophthalmic, nasal or buccal administrations where the limited residence time is a challenge and the active ingredient must be delivered in a faster and effective maner.
  • Test samples Nanoemulsions of Examples 2, 4, 8, 11, 14, 16, 19 and 20.
  • Comparative samples Nanoemulsions of the comparative Examples 24, 25, 26, 30 and 31.
  • the STE test method (OECD TG 491) is an in vitro method that evaluates the eye hazard potential of a test chemical (substances and mixtures) based on its ability to induce cytotoxicity.
  • the aim of this experiment is to characterise the cytotoxic effect of the clobetasol propionate in ophthalmic nanoemulsions.
  • SIRC Serum Serum Institut Rabbit Cornea
  • the test formulations were diluted in physiological saline (PBS) at the determined concentration and the culture medium was replaced by the clobetasol nanoemulsions during 5 minutes. After that, cell viability was determined by MTT assay. Cell mortality was expressed as percentage and it was calculated for each test concentration with regard to the physiological saline control.
  • PBS physiological saline
  • the tested nanoemulsions of the invention showed no cytotoxicity at the tested concentrations and therefore they were classified as minimal irritant by the STE score indicating no eye damage potential. However, the incubation of the compositions of comparative Examples mentioned above showed cytotoxic effects.
  • the nanoemulsions of the present invention do not present ocular hazard potential and must be considered well tolerated at ocular level meanwhile comparative compositions would be irritant and not suitable for ophthalmic administration route.
  • Test samples Nanoemulsions of Examples 2, 4, 8, 11, 14, 16 and 20.
  • Comparative samples Nanoemulsions of the comparative Examples 24, 30 and 31.
  • the HEI-OC1 (House Ear Institute-Organ of Corti-1) cell line is one of the most used auditory cell line available for research purposes.
  • the HEI-OC1 cells express several characteristic molecular markers of the organ of Corti sensory cells (cf. Kalinec GM, et al., "A cochlear cell line as an in vitro system for drug ototoxicity screening”. Audiol. Neurootol. 2003; vol. 8, pp. 177-89 ).
  • the objective of this assay is to test the ototoxic potential of clobetasol propionate nanoemulsions for otic administration.
  • HEI-OC1 cells were plated in sterile 96-well microliter plates and after 24 hours were treated with the clobetasol nanoemulsions diluted in physiological saline (PBS) at 5 % and 0.05 % during 5 minutes. After that, cell viability was determined by MTT assay. Cell mortality was expressed as percentage and it was calculated for each test concentration with regard to the physiological saline control.
  • PBS physiological saline
  • the nanoemulsions of the present invention present low otic irritant potential meanwhile comparative formulations are not adequate for otic administration.
  • Test sample Nanoemulsion of Example 11 of the present invention.
  • Comparative sample Comparative composition of Example 27.
  • Control Samples vehicle of Example 32.
  • Test samples Nanoemulsion of Examples 7 and 10.
  • Control samples Positive control: dexamethasone 0.1 %.
  • Negative control 0.9 % sodium chloride saline solution
  • Examples 7 and 10 The test of the nanoemulsions of the invention (Examples 7 and 10) showed no significant changes in intraocular pressure during the 15-day interval test. In particular, after the administration of the nanoemulsion of Example 7 no statistically significant elevation of the intraocular pressure was observed. Meanwhile, no changes were observed with the administration of the nanoemulsion of Example 10.
  • the nanoemulsions of the present invention should be considered safe during the treatment (that is during the instillation period of 15 days). Comparative samples were not suitable for testing in animal model because of the negative results obtained in the in vitro tolerability tests.
  • Test samples Nanoemulsion of Examples 2, 6, 7, 10, 11, 16, 21 and 22.
  • the THP-1 cell line is an immortal human monocytic cell line derived from an acute monocytic leukemia patient. THP-1 cells were plated, inflammation was induced with LPS and IFN ⁇ and cells were incubated for 24 hours. After that, cells were treated with the test samples The formulations to be tested were diluted with culture medium and culture for other 24 hours. Protein concentration was measured by ELISA, using BDOptEIA Human TNF ⁇ Elisa Set according (BD 555212). The inhibition percentage of cytokine levels was calculated with regard to the stimulated group which was set to 100 % expression levels.
  • Nanoemulsion compositions of the invention showed anti-inflammatory activity reducing the protein expression of TNF ⁇ , with percentages of inhibition close to 100 %. These results confirm the release of active ingredient to the culture medium and the right anti-inflammatory activity.
  • the anti-inflammatory efficacy test is performed in a rabbit acute model of post-operative inflammation created by anterior chamber paracentesis.
  • mice submitted to paracentesis were assigned to different groups: negative control group (negative control samples), comparative test group (comparative sample) and two test groups (test samples).
  • Anterior chamber paracentesis was performed with a needle attached to a syringe and a sample of aqueous humour was removed. After 2 hours from the first paracentesis, a second paracentesis was performed to collect the aqueous humour for biochemical evaluation. Levels of Prostaglandin E2 (PGE2) in the aqueous humour were assessed by ELISA (R&D Systems SKGE004B).
  • the aim of this study is to assess the anti-inflammatory efficacy of the clobetasol propionate of the nanoemulsion of the present invention.
  • Nanoemulsions of the present invention significantly reduced the aqueous humour concentration of PGE 2 compared with the control.
  • the administration of the comparative composition did not show any effect on the PGE 2 biomarker, showing a clear lack of efficacy.
  • the nanoemulsion of the present invention should be considered efficient for the treatment of ocular inflammatory disease or conditions.
  • the comparative compositions 34 and 35 disclosed below are the reproduction of the clobetasol propionate emulsions described in Mohammad Sajid Ali et al (cf. " mohammad Sajid Ali et al. "accelerated Stability Testing of a Clobetasol propionate Loaded nanoemulsion as per ICH guideline”. Scientia Pharmaceutica, 2013, vol. 81, no.4, pp. 1089-1100 ).
  • Table 5 illustrates the quantitative composition of the comparative compositions of Examples 34 and 35, wherein the amount of clobetasol propionate is expressed in mass concentration in relation to the total volume of composition (w/v); meanwhile the amount of the remaining ingredients of the composition is expressed in percentage (%) by volume in relation to the total volume of the composition (v/v).
  • Table 5 Comparative Example Comp. Ex. 34 Comp. Ex.
  • the comparative clobetasol Example 34 having a ratio Smix 1:1 between tween 20 and ethyl alcohol was prepared following the process disclosed by Mohamed Sajid Ali in page 1092 section "preparation of clobetasol propionate nanoemulsion". This section is included herein below: "[...] The optimized nanoemulsion was prepared by dissolving 0.05 % (w/v) of clobetasol propionate (CP) in 15 % (v/v) eucalyptus oil, then a 35 % (v/v) mixture of Tween 20 and ethyl alcohol (1:1 v/v) were added slowly to the oil phase. Then the remaining amount of distilled water was added slowly to get the final preparation of 100 % (v/v). A vortex mixer was used for the vigorous shaking of the mixture (oil, Smix, and water) Colour"
  • the comparative clobetasol Example 35 having a ratio Smix 1:2 between tween 20 and ethyl alcohol was prepared following the process disclosed by Mohamed Sajid in page 1092 section"preparation of clobetasol propionate nanoemulsion” disclosed above but changing the ratio of tween 20 and ethyl alcohol from 1:1 to 1:2.
  • the average droplet size of the comparative Example 34 and 35 was analyzed by Dynamic Light Scattering (DLS).
  • the equipment determined high polidispersion of the sample suggesting values of droplet average size above 6000 nm.
  • the lack of transparency of the comparative examples 34 and 35 is indicative that the droplet sizes of the comparative compositions 34 and 35 disclosed in Mohammad Sajid Ali et al are much higher than a nanoemulsion (translucent). Furthermore, as the droplet size measured by DLS showed high dispersion and droplet size values above 6000 nm, it means that the droplet size of the comparative compositions does not correspond to nanoemulsions droplet average size range (1 - 500 nm).
  • the droplet size of the comparative Examples 34 and 35 was higher than 6,000 nm (which is the high detection point of the DLS) being outside of the claimed range, and then they has to be considered emulsions instead of nanoemulsions.
  • the comparative compositions 34 and 35 were destabilized evolving into three diferentiated phases instead of maintining an homogenous and uniform appearance.
  • the studies were performed at 25 ⁇ 2 °C/60 ⁇ 5 % relative humidity (RH), and changes were observed before 1 week of storage time.
  • the comparative compostions 34 and 35 do not have colloidal stability.
  • Test sample comparative compositions 34 and 35
  • the osmolality is determined by the measurement of the freezing point depression of the sample using an osmometer.
  • the osmolality of the comparative compositions 34 and 35 was higher than the claimed range of the present invention (i.e. 100 mOsm/Kg to 500 mOsm/Kg). Particularly, both comparative compositions had an osmolality higher than 2500 mOsm/Kg. It is specially remarkable that the comparative composition 34 has an osmolality of 2716 mOsm/Kg.
  • the osmolality value of the comparative compositions was much higher than the tolerated osmolality for ophthalmic application, which is from 171 mOsm/kg to 1711 mOsm/kg.
  • compositions 34 and 35 were not appropriate for ophtalmic application.
  • the nasal and otic compositions as well require isotonic or slightly hipertonic or slightly hipotonic compositions due to the sensitivity of nasal and otic tissues. Accordingly compositions 34 and 35 were not suitable for nasal or otic delivery routes of administration.
  • This assay was performed as disclosed in section A.1.1. above but using the comparative compositions 34 and 35 as test samples.
  • the tested comparative compositions 34 and 35 showed cytotoxicity at the tested concentrations and therefore they were classified as toxic by the STE score.
  • This assay was performed as disclosed in section A.1.2. above but using the comparative compositions 34 and 35 as test samples.
  • the HET-CAM is a method which mimics vascular changes in the chorioallantoic membrane, an analogue for ocular conjunctiva, which can be used to determine the potential irritancy of a test substance. This method is based on that described in ICCVAM-Recommended Test Method Protocol: Hen's Egg Test - Chorioallantoic Membrane (HET-CAM) Test Method. NIH Publication No. 10-7533- Published 2010 .
  • Fertilized white SPF (special pathogen free) White Leghorn chicken eggs were incubated at 37 °C and 60 % humidity up to day 10. After determination of the viability of the embryo, a rectangular window was removed from the shell directly over the air cell and the egg membrane was carefully moistened with 2-3 ml 0.9 % saline. After returning to the incubator for 30 minutes, the inner membrane was removed and the test substance was applied to the CAM membrane with a pipette. Eggs were observed continuously for 5 minutes for the appearance of lysis, haemorrhage and/or coagulation and an irritation score (IS) was determined following the ICCVAM-Recommended Test Method Protocol (NIH Publication No. 10-7553-Published 2010 ) guideline.
  • the irritation score (IS) is as follows:
  • HET-CAM ocular irritation assay disclosed above was performed and the corresponding representative images of the tested samples were done (cf. Fig. 1 ).
  • the representative images reflected that the nanoemulsions of the present invention did not trigger any lysis, haemorrhage or coagulation processes, meanwhile the representative images reflected that the comparative composition 34 were irritant.
  • the irritation score (IS) of the composition of Ex. 7 and 11 and the comparative composition 34 were also determinated.
  • the values of the IS are disclosed in the Table below: Example Number IS Examples 7 and 11 0.07 Non irritant Comparative composition 34 14.46 Severe irritant
  • compositions of the invention are non-irritant meanwhile the comparative compositions disclosed in Mohammad Sajid Ali et al were considered irritant and therefore, not suitable for being use as a medicament according to the proposed use of this invention.
  • compositions disclosed in Mohammad Sajid Ali et al. were non-transparent emulsions having a droplet average size higher than 6,000 nm and an osmolality higher than 2500 mOsm / kg. Furthermore, the ratio oil/clobetasol is 272 and the ratio surfactant/clobetasol is 385, both higher than the claimed range in the compositions of the present invention.
  • compositions disclosed in Mohammad Sajid Ali et al. did not have colloidal stability and also these compositions are irritant and therefore, not suitable for being used as a medicament.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
EP18700437.9A 2017-06-23 2018-01-18 An oil-in-water nanoemulsion composition of clobetasol Active EP3641728B9 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL18700437T PL3641728T3 (pl) 2017-06-23 2018-01-18 Kompozycja klobetazolu w postaci nanoemulsji typu olej w wodzie
SI201830297T SI3641728T1 (sl) 2017-06-23 2018-01-18 Sestavek nanoemulzije klobetazola olja v vodi
HRP20210865TT HRP20210865T1 (hr) 2017-06-23 2021-05-31 Ulje-u-vodi nanoemulzijski pripravak klobetazola

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382393 2017-06-23
PCT/EP2018/051218 WO2018233878A1 (en) 2017-06-23 2018-01-18 OIL NANOEMULSION COMPOSITION IN CLOBETASOL WATER

Publications (3)

Publication Number Publication Date
EP3641728A1 EP3641728A1 (en) 2020-04-29
EP3641728B1 EP3641728B1 (en) 2021-03-10
EP3641728B9 true EP3641728B9 (en) 2021-06-30

Family

ID=59285129

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18700437.9A Active EP3641728B9 (en) 2017-06-23 2018-01-18 An oil-in-water nanoemulsion composition of clobetasol

Country Status (32)

Country Link
US (1) US10857160B2 (ko)
EP (1) EP3641728B9 (ko)
JP (1) JP7065895B2 (ko)
KR (1) KR102571107B1 (ko)
CN (1) CN110944625B (ko)
AU (1) AU2018288256B2 (ko)
CA (1) CA3067657A1 (ko)
CL (1) CL2019003707A1 (ko)
CO (1) CO2020000026A2 (ko)
CR (1) CR20200024A (ko)
CY (1) CY1124193T1 (ko)
DK (1) DK3641728T3 (ko)
DO (1) DOP2019000307A (ko)
EC (1) ECSP19089679A (ko)
ES (1) ES2875851T3 (ko)
HR (1) HRP20210865T1 (ko)
HU (1) HUE055016T2 (ko)
IL (1) IL271474B (ko)
LT (1) LT3641728T (ko)
MX (1) MX2019015410A (ko)
MY (1) MY190953A (ko)
PE (1) PE20200736A1 (ko)
PH (1) PH12019550291A1 (ko)
PL (1) PL3641728T3 (ko)
PT (1) PT3641728T (ko)
RU (1) RU2759901C2 (ko)
SA (1) SA519410841B1 (ko)
SG (1) SG11201912393XA (ko)
SI (1) SI3641728T1 (ko)
TW (1) TWI768056B (ko)
WO (1) WO2018233878A1 (ko)
ZA (1) ZA202000128B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005726A1 (en) * 2022-06-30 2024-01-04 Ilko Ilac Sanayi Ve Ticaret A.S. Storage stable topical composition comprising clobetasol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
US8449867B2 (en) * 2004-08-31 2013-05-28 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
ES2429040T5 (es) * 2004-08-31 2017-06-13 Stiefel Research Australia Pty Ltd Método y composiciones de microemulsión y emulsión submicrónica
FR2889662B1 (fr) * 2005-08-11 2011-01-14 Galderma Res & Dev Emulsion de type huile-dans-eau pour application topique en dermatologie
CN102026623B (zh) * 2008-05-14 2013-08-14 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
US20110045050A1 (en) * 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
MX2013004296A (es) * 2010-10-21 2013-09-26 Cadila Healthcare Ltd Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis.
US9789123B2 (en) 2010-10-21 2017-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
CN102283850B (zh) * 2011-08-25 2013-04-10 西北农林科技大学 一种水包油型复方酮康唑纳米药物及其制备方法
KR20170113568A (ko) * 2015-02-06 2017-10-12 알.피.쉐러 테크놀러지즈 엘엘씨 폴리머 안정화된 약학 제제용 수중 유 에멀전의 제조
CA2976952A1 (en) 2015-03-05 2016-09-09 Allergan, Inc. Self-emulsifying drug delivery system (sedds) for ophthalmic drug delivery
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
WO2016205001A1 (en) * 2015-06-18 2016-12-22 Valeant Pharmaceuticals North America Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis
WO2017037663A1 (en) * 2015-09-02 2017-03-09 Cadila Healthcare Limited Topical compositions comprising corticosteroids

Also Published As

Publication number Publication date
ZA202000128B (en) 2021-01-27
CA3067657A1 (en) 2018-12-27
SI3641728T1 (sl) 2021-08-31
US20190298737A1 (en) 2019-10-03
CY1124193T1 (el) 2022-05-27
DOP2019000307A (es) 2020-03-15
DK3641728T3 (da) 2021-06-07
TWI768056B (zh) 2022-06-21
CO2020000026A2 (es) 2020-04-24
JP2020524672A (ja) 2020-08-20
SG11201912393XA (en) 2020-01-30
HRP20210865T1 (hr) 2021-08-20
RU2019144015A (ru) 2021-07-23
ES2875851T3 (es) 2021-11-11
AU2018288256A1 (en) 2020-01-30
CL2019003707A1 (es) 2020-06-05
CR20200024A (es) 2020-03-12
WO2018233878A1 (en) 2018-12-27
JP7065895B2 (ja) 2022-05-12
TW201904562A (zh) 2019-02-01
PE20200736A1 (es) 2020-07-23
RU2019144015A3 (ko) 2021-07-23
ECSP19089679A (es) 2020-05-29
AU2018288256B2 (en) 2023-09-28
CN110944625A (zh) 2020-03-31
RU2759901C2 (ru) 2021-11-18
US10857160B2 (en) 2020-12-08
IL271474A (en) 2020-01-30
EP3641728B1 (en) 2021-03-10
IL271474B (en) 2022-09-01
LT3641728T (lt) 2021-08-10
PH12019550291A1 (en) 2021-01-11
HUE055016T2 (hu) 2021-10-28
SA519410841B1 (ar) 2022-06-05
CN110944625B (zh) 2022-05-03
EP3641728A1 (en) 2020-04-29
MY190953A (en) 2022-05-24
KR20200019945A (ko) 2020-02-25
PL3641728T3 (pl) 2021-09-20
KR102571107B1 (ko) 2023-08-25
MX2019015410A (es) 2021-09-30
PT3641728T (pt) 2021-06-14

Similar Documents

Publication Publication Date Title
EP2136782B1 (en) Ophthalmic oil-in-water emulsions containing prostaglandins
RU2639472C2 (ru) Офтальмическая композиция
US20090286718A1 (en) Stable Aqueous Cyclosporin Compositions
KR101786760B1 (ko) 프로스타글란딘을 함유하는 음이온성 수중유형 에멀젼 및 그의 용도
Patel et al. Development and evaluation of dexamethasone nanomicelles with potential for treating posterior uveitis after topical application
US20240207195A1 (en) Ocular drug delivery
EP3641728B9 (en) An oil-in-water nanoemulsion composition of clobetasol
KR101813211B1 (ko) 프로스타글란딘을 함유하는 양이온성 수중유형 에멀젼 및 그의 용도
JP2022506684A (ja) 人工涙液
AU2018372185A1 (en) Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US8969305B2 (en) Aqueous ophthalmic solution based on cyclosporin
WO2023016583A1 (zh) 一种芦可替尼组合物及其用途
US20230093908A1 (en) In-situ Gel Containing Cyclosporine Micelles as Sustained Ophthalmic Drug Delivery System
TR201612233A1 (tr) Oftalmi̇k farmasöti̇k bi̇leşi̇mler

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602018013701

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0009000000

Ipc: A61K0031573000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/107 20060101ALI20201022BHEP

Ipc: A61K 47/34 20170101ALI20201022BHEP

Ipc: A61K 47/26 20060101ALI20201022BHEP

Ipc: A61K 31/573 20060101AFI20201022BHEP

Ipc: A61K 47/14 20170101ALI20201022BHEP

Ipc: A61P 29/00 20060101ALI20201022BHEP

Ipc: A61K 9/00 20060101ALI20201022BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DELGADO GANAN, MARIA ISABEL

Inventor name: LENDINEZ GRIS, MARIA DEL CARMEN

Inventor name: SANAGUSTIN AQUILUE, JAVIER

INTG Intention to grant announced

Effective date: 20201112

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LABORATORIOS SALVAT, S.A.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029495

Country of ref document: HK

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1369046

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018013701

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG B9

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20210865T

Country of ref document: HR

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

Ref country code: DK

Ref legal event code: T3

Effective date: 20210603

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3641728

Country of ref document: PT

Date of ref document: 20210614

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210608

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20210401415

Country of ref document: GR

Effective date: 20210709

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20210310

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 37384

Country of ref document: SK

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20210865

Country of ref document: HR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210310

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E055016

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210310

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2875851

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018013701

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210865

Country of ref document: HR

Payment date: 20220104

Year of fee payment: 5

26N No opposition filed

Effective date: 20211213

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20220104

Year of fee payment: 5

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210865

Country of ref document: HR

Payment date: 20230103

Year of fee payment: 6

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1369046

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210310

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230513

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210865

Country of ref document: HR

Payment date: 20240105

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240126

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240129

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240126

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240104

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240103

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240129

Year of fee payment: 7

Ref country code: ES

Payment date: 20240201

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240104

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20240105

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20240112

Year of fee payment: 7

Ref country code: RO

Payment date: 20240105

Year of fee payment: 7

Ref country code: HU

Payment date: 20240111

Year of fee payment: 7

Ref country code: FI

Payment date: 20240125

Year of fee payment: 7

Ref country code: DE

Payment date: 20240129

Year of fee payment: 7

Ref country code: CZ

Payment date: 20240105

Year of fee payment: 7

Ref country code: CY

Payment date: 20240105

Year of fee payment: 7

Ref country code: BG

Payment date: 20240129

Year of fee payment: 7

Ref country code: PT

Payment date: 20240108

Year of fee payment: 7

Ref country code: GB

Payment date: 20240129

Year of fee payment: 7

Ref country code: CH

Payment date: 20240202

Year of fee payment: 7

Ref country code: SK

Payment date: 20240103

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20240104

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240127

Year of fee payment: 7

Ref country code: PL

Payment date: 20240109

Year of fee payment: 7

Ref country code: NO

Payment date: 20240129

Year of fee payment: 7

Ref country code: MT

Payment date: 20240103

Year of fee payment: 7

Ref country code: LV

Payment date: 20240103

Year of fee payment: 7

Ref country code: IT

Payment date: 20240122

Year of fee payment: 7

Ref country code: HR

Payment date: 20240105

Year of fee payment: 7

Ref country code: FR

Payment date: 20240125

Year of fee payment: 7

Ref country code: DK

Payment date: 20240125

Year of fee payment: 7

Ref country code: BE

Payment date: 20240129

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210310

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20240109

Year of fee payment: 7